News Agency
The Times

VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism

  • Written by PR Newswire
  • 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p <0.0001)
  •  Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug.

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- VISEN Pharmaceuticals, an...

Read more: VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide...

How Does Temporary Fencing Help Simplify Project Planning?

Why Does Temporary Fencing Matter During Project Planning?  A controlled boundary is essential when construction, infrastructure maintenance, demolition,  landscaping, and other projects are underway. That is when temporary fencing becomes an important  option to consider. The fencing layout affects more than site... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion